formodual (100 mcg + 6 mcg)/dawkę inh. aerozol inhalacyjny, roztwór
chiesi farmaceutici s.p.a. - beclometasoni dipropionas + formoteroli fumaras - aerozol inhalacyjny, roztwór - (100 mcg + 6 mcg)/dawkę inh.
fostex (100 mcg + 6 mcg)/dawkę aerozol inhalacyjny, roztwór
chiesi farmaceutici s.p.a. - formoteroli fumaras + beclometasoni dipropionas - aerozol inhalacyjny, roztwór - (100 mcg + 6 mcg)/dawkę
fostex nexthaler (100 mcg + 6 mcg)/dawkę inh. proszek do inhalacji
chiesi farmaceutici s.p.a. - beclometasoni dipropionas + formoteroli fumaras - proszek do inhalacji - (100 mcg + 6 mcg)/dawkę inh.
duastmin 120 mcg + 20 mcg proszek do inhalacji w kapsułce twardej
laboratoires smb - budesonidum + salmeterolum - proszek do inhalacji w kapsułce twardej - 120 mcg + 20 mcg
duastmin 240 mcg + 20 mcg proszek do inhalacji w kapsułce twardej
laboratoires smb - salmeterolum + budesonidum - proszek do inhalacji w kapsułce twardej - 240 mcg + 20 mcg
acatar acti-tabs 60 mg + 2,5 mg tabletki
us pharmacia sp. z o.o. - pseudoephedrini hydrochloridum + tripirolidini hydrochloridum - tabletki - 60 mg + 2,5 mg
polopiryna complex 500 mg + 15,58 mg + 2 mg proszek do sporządzania roztworu doustnego
zakłady farmaceutyczne polpharma s.a. - acidum acetylsalicylicum + phenylephrini bitartras + chlorphenamini maleas - proszek do sporządzania roztworu doustnego - 500 mg + 15,58 mg + 2 mg
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - preparaty do obturacyjne choroby dróg oddechowych, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - preparaty do obturacyjne choroby dróg oddechowych, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
trimbow
chiesi farmaceutici s.p.a. - beclometasone beklometazonu, formoterola fumaran dihydrat, glycopyrronium bromek - choroba płuc, przewlekła obturacyjna - preparaty do obturacyjne choroby dróg oddechowych, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.